| Developers: | Carmat |
| Branches: | Pharmaceuticals, medicine, healthcare |
Content |
2021
First heart implantation to a woman
On September 21, 2021, the French artificial manufacturer hearts Carmat announced that it had carried out the first implantation of its artificial hearts Aeson to a woman. The company said the procedure was performed at UofL Health - Jewish Hospital by doctors at the University of Louisville at. USA
The Aeson artificial heart is designed for patients suffering from terminal biventricular heart failure, and it can also work for several months while waiting for a live organ transplant. The heart received the name Aeson in honor of the character of ancient Greek mythology Eson, who managed to regain his youth.
The artificial heart system consists of an implanted prosthesis, external equipment and a medical aid console designed to control the prosthesis during implantation and monitor the operation of the device.
The Aeson artificial heart consists of several parts:
1. Motor-pump unit consists of two micro pumps that push executive fluid to membranes and generate systole and diastole.
2. Ventricular chambers divided by membrane into two parts, one for blood, the other for executive fluid. The blood contact layer of this membrane is made of biocompatible materials.
3. Built-in electronics, microprocessors and integrated sensors allow you to respond to the patient's physiological needs in a self-regulating manner.
4. The flexible outer pocket holds the drive fluid.
5. Four biological valves at the inlet and outlet provide unidirectional pulsating blood flow.
6. Two exit conductors connecting the prosthesis with the pulmonary artery and aorta.
7. A twisted gear connecting the prosthesis to external components.
 | This third implantation in the USA was a landmark event not only because it allowed us to complete the recruitment of the first cohort of patients as part of a feasibility study, but also, crucially, because for the first time in history, our device helped a woman suffering from heart failure, said Carmat CEO Stefan Piat in a statement. |  |
Prosthesis, provides mobility and autonomy necessary for the conduct of almost normal life. The heart weighs 4 kg and includes a joystick and two pockets for batteries, providing autonomy of about 4 hours. The medical team uses a hospital console (HCC) to manage the prosthesis during implantation and to monitor/monitor the operation of the device.
In November 2019, interim results from this study on 11 implanted patients showed that 73% of these patients achieved six months of survival with the prosthesis pending subsequent successful heart transplantation. In addition to the United States, artificial heart transplant operations were performed in Denmark, the Czech Republic, France and Kazakhstan.[1]
First artificial heart implantation surgery
At the end of July 2021, Carmat introduced the fully artificial Aeson heart, designed to treat people with terminal stage biventricular heart failure.
The first operation using the Aeson implant was performed by a team of cardiac surgeons led by Dr. Ciro Maiello at Azienda Ospedaliera dei Colli Hospital in Naples. This implant was the first artificial heart sold by Carmat since its inception in 2008.'
In accordance with the adopted strategy, in 2021 Carmat intends to focus its marketing efforts on the sale of the Aeson artificial heart in Germany and several other EU countries, including Italy. In December 2020, the company received the approval of the European regulator and initiated negotiations with the twenty most active German clinics that conduct such operations and may be interested in acquiring an artificial heart.
According to the developers, these discussions confirmed the interest of the medical community in a new type of therapy, which is considered a truly innovative alternative to a traditional heart transplant. Duke University Hospital cardiac surgical teams estimate the number of new heart failure cases in the U.S. as 100,000 per year, but only 3,000 to 4,000 of these patients may benefit from heart transplantation. The remaining 96,000 patients need other therapies and may become candidates for artificial heart implantation developed by Carmat.
Five German hospitals have already completed the training offered by Carmat and are screening patients to select candidates for implantation. It is expected that the operations will be carried out throughout the year and thereby ensure a steady demand for the Aeson artificial heart after the implant enters the market.[2]
2020: Start of sales of artificial heart Carmat
At the end of December 2020, the French company Carmat received permission to sell in Europe the world's first fully artificial heart. The novelty will enter the commercial market in the second quarter of 2021.
Against the backdrop of this event, Carmat shares rose more than 50%, which marks the highest increase in value in seven years. As a result, the company's capitalization reached $496 million. The company's managing director, Stephane Piat, called obtaining permission a "historic event." According to him, from 2021, Carmat will begin to collaborate with doctors and medical centers to look for patients who need a heart transplant.
The artificial heart will be used during the transition stage in heart transplants to patients with severe cardiovascular diseases, for example, with terminal heart failure. The development of Carmat is primarily intended for patients with contraindications to drug therapy and the installation of an auxiliary device for the left ventricle. The donor heart of the patient needs to be transplanted within 180 days after installation of the artificial heart.
Development of artificial heart began in 1993 when the surgeon and the inventor of an artificial heart valve Alain Carpentier offered the French industrialist Jean-Luc Lagardere the idea of creation of artificial heart. Carpentier received several laboratories for work and took control of a number of Lagardier engineers called Matra. Gradually, the project expanded, and now its main shareholder is Airbus, which included Matra. Carpentier and Lagardier own the main stake in the company.[3]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |